Cogent Biosciences Reports Q3 Loss of $111.4 Million
The Waltham-based biotech reported third-quarter 2026 results and announced FDA acceptance of its bezuclastinib application for Advanced Systemic Mastocytosis.
Updated on Nov. 5, 2026 in Corporate Finance

Cogent Biosciences reported third-quarter 2026 financial results, with a net loss of $111.4 million and cash, cash equivalents and marketable securities of $791.1 million as of September 30, 2026. The company also announced FDA acceptance of its New Drug Application for bezuclastinib in Advanced Systemic Mastocytosis.
Why it matters
The results show a company spending heavily as it prepares for a potential commercial launch of bezuclastinib, with several regulatory decisions ahead. The reported cash position is the funding base for that spending.
The company reported $791.1 million in cash, cash equivalents and marketable securities as of September 30, 2026, against a nine-month 2026 net loss of $305.2 million. The stub does not provide the market reaction or any prior-period comparison for these figures.
The players
Cogent Biosciences
A clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, with a co-headquarters in Boulder, Colorado, focused on targeted therapies for mast cell-driven diseases.
The details
Research and development expenses rose primarily on costs for the SUMMIT, PEAK and APEX clinical trials, while general and administrative expenses increased on commercial readiness and infrastructure for a potential bezuclastinib launch. The company also initiated a 40-patient extension cohort of its PEAK trial.
Timeline
September 30, 2026: Quarter end, when the $791.1 million cash balance was reported.
November 30, 2026: PDUFA action date for bezuclastinib in gastrointestinal stromal tumors.
December 30, 2026: PDUFA action date for bezuclastinib in non-advanced systemic mastocytosis.
June 29, 2027: PDUFA action date for bezuclastinib in Advanced Systemic Mastocytosis.
Market Dynamics
The company's three bezuclastinib PDUFA dates fall within standard PDUFA review timelines, which set the framework for when approval decisions arrive. Its cash runway into late 2028 is set against that review calendar.
Investors tracking Cogent Biosciences face a cash position the company says will fund operations into late 2028, but the stock's value depends on regulatory decisions still months away. Shareholders should weigh the ongoing quarterly losses against the pending approval timeline.
The takeaway
Cogent Biosciences is spending heavily ahead of multiple FDA decisions, so its funding runway and the timing of those decisions are the key factors to track. The company has said its cash supports operations into late 2028.
What happens next
Upcoming regulatory milestones include a PDUFA action date for bezuclastinib in gastrointestinal stromal tumors on November 30, 2026, and presentations at the ASH Annual Meeting December 12-15, 2026.
Further reading
For more on how biotech companies fund late-stage development, see Corporate Finance coverage in Waltham.






